Inhibrx Год IPO
Что обозначает Год IPO в Inhibrx?
Год IPO Inhibrx, Inc. является 2020
Какое определение для Год IPO?
Первичное публичное размещение акций - это тип публичного предложения, при котором акции компании обычно продаются институциональным инвесторам, которые, в свою очередь, впервые продают эти акции широкой публике на фондовой бирже.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
Год IPO компаний в Health Care сектор на NASDAQ по сравнению с Inhibrx
Что делает Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Компании с год ipo похож на Inhibrx
- Acusensus Ltd имеет Год IPO из 2019
- Grayscale Ethereum Trust (ETH) имеет Год IPO из 2019
- Powerwrap Ltd имеет Год IPO из 2019
- Powerwrap имеет Год IPO из 2019
- National Rural Utilities Cooper имеет Год IPO из 2019
- Listed Funds Trust имеет Год IPO из 2019
- Inhibrx имеет Год IPO из 2020
- Globally Local Technologies имеет Год IPO из 2021
- uniQure N.V имеет Год IPO из 2021
- Trustpilot plc имеет Год IPO из 2021
- IQVIA имеет Год IPO из 2021
- ACTIA S.A имеет Год IPO из 2021
- Remark имеет Год IPO из 2021